SFXN2

Across TCGA pan-cancer cohorts, SFXN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SFXN2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SFXN2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SFXN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where SFXN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.622	0.367	<.001	45	view →
LSCC	OS	Median	III,IV	0.938	0.406	<.001	21	view →
CCRCC	OS	Median	II,III,IV	1.000	0.435	.015	11	view →
LUAD	OS	Tertile	III,IV	0.716	0.273	.018	4	view →
GBM	OS	Median	All	0.387	0.604	.012	3	view →
HNSC	DFS	Tertile	IV	0.788	0.563	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SFXN2–PDAC (OS)

Open the PDAC breakdown →